Dr. Amina Zoubeidi's project, Reversing Neuroendocrine Prostate Cancer (NEPC), was rated as one of the Top 5 Research Stories at The 25th Annual Prostate Cancer Foundation Scientific Retreat, held October 26- 28, at the La Costa Resort in Carlsbad, CA.
The Prostate Cancer Foundation's Science Department rated the topics or discoveries discussed during the Scientific Retreat, and described each of the top five on their website. For Dr. Zoubeidi, the description is:
Neuroendocrine prostate cancer (NEPC) is a highly aggressive and lethal form of prostate cancer that affects ~17% of patients with advanced CRPC. Because this form of prostate cancer is so aggressive, there is an urgent need to develop new and effective treatments for patients with NEPC. PCF-funded researcher Dr. Amina Zoubeidi (Vancouver Prostate Centre) has discovered a “regulator” gene (EZH2) that controls NEPC. When enzalutamide-resistant prostate cancer cells are given EZH2-inhibitors, they revert and become treatable again with enzalutamide. EZH2 inhibitors are now in clinical trials for advanced prostate cancer.